1-2 of 2
Jon M. Wigginton, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Geoffrey L. Uy, MD, Ibrahim Aldoss, MD, Matthew C Foster, MD, David A Sallman, MD, Kendra L. Sweet, MD, David A. Rizzieri, MD, Peter H. Sayre, MD PhD, Anjali S. Advani, MD, Ashkan Emadi, MD, Matthew J. Wieduwilt, MD PhD, Norbert Vey, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Tamara Moyo, MD PhD, Sarah E. Church, PhD, Michael P. Rettig, PhD, Martha L. Arellano, MD, John E. Godwin, MD, Bob Löwenberg, MD PhD, Gerwin Huls, MD PhD, Farhad Ravandi, MD, John Muth, MS, Kathy Tran, Mojca Jongen-Lavrencic, MD PhD, Erin Timmeny, Max S. Topp, MD, Stefania Paolini, MD PhD, Kuo Guo, MSc, Teia Curtis, Jian Zhao, PhD, Jayakumar Vadakekolathu, PhD, Jon M. Wigginton, MD, Ezio Bonvini, MD, Sergio Rutella, MDPhDFRCPath, Roland B. Walter, MD PhD MS, Jan K Davidson-Moncada, MD PhD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 733.
https://doi.org/10.1182/blood-2019-122073
Published: 2019
Journal Articles

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Maria Calbacho, MD, Jordi Sierra Gil, MD PhD, Jaime Perez De Oteyza, MD PhD, Jacob M. Rowe, MB, BS, Ofir Wolach, MD, Yishai Ofran, MD, Yakir Moshe, MD, Jichao Sun, PhD, Jan Baughman, MPH, Eileen McNulty, MS, Ezio Bonvini, MD, Jon M. Wigginton, MD, Jan K Davidson-Moncada, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2662.
https://doi.org/10.1182/blood-2019-125966
Published: 2019